Mosaic ImmunoEngineering
Mosaic ImmunoEngineering Inc. is a development-stage biotechnology company focused on advancing and commercializing proprietary immunostimulatory platform technology derived from a plant virus, cowpea mosaic virus. The company is dedicated to developing immunotherapies to treat and prevent cancer and infectious diseases, with a focus on both human and veterinary applications. Supported by federal research grants and private foundations, Mosaic aims to bring innovative immuno-oncology and vaccine solutions to market, leveraging its unique platform technology and experienced leadership team.
Industries
Nr. of Employees
small (1-50)
Mosaic ImmunoEngineering
Products
Lead human intratumoral plant-virus-derived immunostimulant (clinical candidate)
A non-replicating plant-virus nanoparticle designed for intratumoral administration to activate multi-PRR innate immune pathways, induce adaptive anti-tumor responses, and be evaluated in Phase 1 clinical trials.
Veterinary intratumoral plant-virus-derived immunostimulant (canine development candidate)
A companion-animal formulation and program evaluating intratumoral nanoparticle immunotherapy in dogs with naturally occurring tumors to generate translational data and support veterinary commercialization.
Modular plant-virus-based vaccine platform and delivery devices
A platform that links selected peptide epitopes to plant-virus nanoparticles and integrates them into microneedle patches or biodegradable implants for targeted immune responses and potential single-administration protection.
Lead human intratumoral plant-virus-derived immunostimulant (clinical candidate)
A non-replicating plant-virus nanoparticle designed for intratumoral administration to activate multi-PRR innate immune pathways, induce adaptive anti-tumor responses, and be evaluated in Phase 1 clinical trials.
Veterinary intratumoral plant-virus-derived immunostimulant (canine development candidate)
A companion-animal formulation and program evaluating intratumoral nanoparticle immunotherapy in dogs with naturally occurring tumors to generate translational data and support veterinary commercialization.
Modular plant-virus-based vaccine platform and delivery devices
A platform that links selected peptide epitopes to plant-virus nanoparticles and integrates them into microneedle patches or biodegradable implants for targeted immune responses and potential single-administration protection.
Services
Design and execution of in vivo efficacy studies in rodent tumor models and naturally occurring canine cancers, immune biomarker analysis, and combination therapy evaluation.
Development of modular peptide-conjugated nanoparticle vaccines and incorporation into microneedle patches and implantable polymer devices for slow-release and room-temperature stable delivery.
Preparation for IND filings including planning for GMP manufacturing, nonclinical toxicology studies, and related regulatory activities to support first-in-human trials.
Design and execution of in vivo efficacy studies in rodent tumor models and naturally occurring canine cancers, immune biomarker analysis, and combination therapy evaluation.
Development of modular peptide-conjugated nanoparticle vaccines and incorporation into microneedle patches and implantable polymer devices for slow-release and room-temperature stable delivery.
Preparation for IND filings including planning for GMP manufacturing, nonclinical toxicology studies, and related regulatory activities to support first-in-human trials.
Expertise Areas
- Intratumoral in situ vaccination
- Preclinical oncology research
- Comparative oncology (companion animal studies)
- Nanoparticle vaccine and immunotherapy platform development
Key Technologies
- Plant-virus-derived nanoparticles
- Intratumoral nanoparticle administration
- Pattern recognition receptor (PRR) / toll-like receptor (TLR) activation
- Peptide epitope conjugation